Glucotrack to File Significant IDE with FDA for US Clinical Trial in Early Q2 Based on Critical 2025 Milestones
Glucotrack, Inc. announced significant progress towards filing an Investigational Device Exemption (IDE) with the U.S. FDA in Q2 2026 to initiate a U.S. clinical trial for its implantable continuous blood glucose monitoring system. Following successful first-in-human trials in Brazil and a follow-up study in Australia, the company completed key tri…